Injectable artesunate

Please refer to the full prescribing information and/or patient information supplied by the relevant marketing authorization holder for your country, as well as local policies and treatment guidelines as they may vary from country to country.

Manufacturers listed on this page meet internationally agreed quality standards. For more information on quality assured medicines, refer to the WHO Prequalification Programme and the Global Fund's strategy on quality assurance of medicines

Manufacturer Registration status Formulation
Guilin Pharmaceutical Co., Ltd. WHO prequalified

Artesunate 30 mg, 60mg and 120mg powder for injection; 1 vial of artesunate powder is co-packed with 1 ampoule of sodium bicarbonate injection and 1 ampoule of sodium chloride injection 

Injectable artesunate is administered intravenously (IV) or intramuscularly (IM) for the treatment of severe malaria caused by P. falciparum. In the Guidelines for the Treatment of Malaria 3rd edition, the WHO strongly recommends the use of IV or IM artesunate in adults and children suffering from severe malaria (including infants, pregnant women in all trimesters, and lactating women) for at least 24 hours and until the patient can tolerate a full course of oral ACT therapy. 

Dosing table

Dosing table for IV artesunate treatment
Category Dose
Children <20kg 3 mg/kg bodyweight per dose
Children and adults >20kg 2.4 mg/kg bodyweight per dose

*When using artesunate as an IM injection, give adults and children a single intramuscular dose of artesunate (as a pre-referral) and refer to an appropriate facility for further care. 

Dosing regimen:

  • Day 1 Dose 1: on admission (0 Hours)
  • Day 1 Dose 2: 12 hours later
  • Day 2 Dose 3: 24 hours after first dose

National malaria treatment guideline adoption of injectable artesunate

*Information based on available National Treatment Guidelines